New Stock News | Tianchen Biomedical Medicine Passes Hong Kong Stock Exchange Hearing for LP-003 to Sprint Phase III Clinical Trial

According to the latest information from the Securities Times App, it was disclosed by the Hong Kong Stock Exchange on May 21 that Tianchen Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Tianchen Biopharmaceutical") has passed the listing hearing on the main board of the Hong Kong Stock Exchange, with Guojin Securities (Hong Kong) as the exclusive sponsor.